Epileptic Seizures in Newly Diagnosed and Recurrent IDH-Wildtype Glioblastoma

Overview

This study analyzes the clinical characteristics and risk factors of glioma-related epilepsy (GRE) in patients with newly diagnosed and recurrent IDH-wildtype glioblastoma (GBM) based on the 2021 WHO CNS tumor classification. It highlights the incidence, seizure control outcomes, and implications for postoperative management in this patient population.

Background

Glioblastoma (GBM), IDH-wildtype, is a highly aggressive primary CNS tumor with a poor prognosis. Glioma-related epilepsy (GRE) is a common and debilitating comorbidity in adult diffuse gliomas, with incidence varying by tumor pathology and grade. The 2021 WHO classification redefined GBM, emphasizing the need to reassess GRE characteristics under this updated framework. Understanding GRE in IDH-wildtype GBM is crucial for improving patient quality of life and seizure management.

Data Highlights

The study retrospectively reviewed adult patients with GBM, IDH-wildtype, undergoing surgery between 2015 and 2021. GRE was assessed preoperatively and seizure control was monitored for one year postoperatively. Tumor molecular markers including MGMT promoter status were analyzed. Surgical extent was categorized as gross total resection (GTR) or non-GTR. Adjuvant therapies and survival outcomes were also recorded.

Key Findings

• GRE incidence in IDH-wildtype GBM patients was significant, with seizures occurring both preoperatively and postoperatively.
• Postoperative seizure control was suboptimal in a subset of patients despite prophylactic anti-seizure medication and standard adjuvant therapies.
• Molecular markers such as MGMT promoter methylation were included in the analysis, though limited by testing availability.
• Gross total resection was assessed as a factor potentially influencing seizure outcomes.
• Recurrent GBM patients exhibited distinct seizure profiles compared to newly diagnosed cases.

Clinical Implications

Clinicians should recognize the high prevalence and challenging control of GRE in IDH-wildtype GBM patients. Comprehensive preoperative assessment and tailored postoperative anti-seizure strategies are essential. Surgical extent and molecular tumor characteristics may inform seizure risk stratification and management planning.

Conclusion

This study underscores the importance of evaluating and managing epileptic seizures in patients with IDH-wildtype GBM within the context of the 2021 WHO classification. Improved understanding of GRE characteristics can enhance clinical care and patient quality of life.

Related Resources & Content

1. Wang et al. 2021 -- Epileptic Seizures Associated with Gliomas in Patients with Newly Diagnosed and Recurrent IDH-Wildtype Glioblastoma